|
Real-time Estimate
Cboe BZX
20:06:05 12/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 150.06 USD | -0.73% |
|
+3.67% | +22.16% |
| 07:29pm | Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says | MT |
| 03:19pm | BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 187,444 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 23.09% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 207,447 | 199,984 | 193,209 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 22.33% | -3.6% | -3.39% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.8x | 18.8x | 17.4x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 13.2x | 9.33x | 7.11x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.05x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.1x | 5.72x | 5.44x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.75x | 6.11x | 5.61x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 26.3x | 11.2x | 10.5x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 63.5x | 12.6x | 11.4x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -394x | 13.9x | 13.9x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.25% | 7.2% | 7.18% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.293 | 3.352 | 3.015 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.18% | 2.22% | 1.99% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.298 | 8.021 | 8.703 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -99.9% | 41.8% | 34.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,725 | 32,745 | 34,430 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,885 | 17,879 | 18,401 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,268 | 15,901 | 16,975 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,257 | 10,268 | 10,910 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 20,003 | 12,540 | 5,765 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 151.17 | 151.17 | 151.17 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 2/1/22 A | 2/2/23 A | 2/6/24 A | 2/11/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -45.84x | 6.75x | 26.31x | 2.18% | 187B | |
| 33.55x | 12.18x | 25.21x | 0.58% | 1,051B | |
| 29x | 6.42x | 18.31x | 2.04% | 630B | |
| 35.19x | 8.13x | 16.76x | 2.51% | 489B | |
| 111.24x | 5.93x | 25.27x | 2.34% | 359B | |
| 19.31x | 4.72x | 11.72x | 2.8% | 344B | |
| 20.06x | 5.27x | 12.98x | 3.02% | 272B | |
| 20.56x | 4.21x | 12.07x | 2.1% | 246B | |
| 26.34x | 6.83x | 12.21x | 2.43% | 224B | |
| 11.36x | 4.15x | 8.6x | 4.47% | 169B | |
| Average | 26.08x | 6.46x | 16.94x | 2.45% | 397.28B | |
| Weighted average by Cap. | 31.99x | 7.69x | 18.87x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
